Patents by Inventor Sergey V. Menis

Sergey V. Menis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Engineered outer domain (EOD) of HIV GP120 and mutants thereof
    Patent number: 10421789
    Abstract: The invention relates to an engineered outer domain (eOD) of HIV gp120 and mutants thereof and methods of making and using the same. The mutant eODs may be advantageous for the elicitation of CD4-binding site (CD4bs)-directed broadly-neutralizing antibodies (bnAbs) and/or improve binding to mature VRC01 and/or improve binding to germline VRC01 and the germlines of other VH1-2 derived broadly-neutralizing antibodies. The mutant eODs may also include glycan-masking mutations on eOD. The present invention also includes fusions of eOD to various protein multimers to enhance immunogenicity as well as the design of cocktails of different eODs that represent the full diversity of HIV sequences within the VRC01 epitope and surroundings.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: September 24, 2019
    Assignees: University of Washington, Center for Commercialization, The Scripps Research Institute, International AIDS Vaccine Initiative
    Inventors: Po-Ssu Huang, Joseph Graham Jardine, Sergey V. Menis, William Ray Schief, Neil P. King
  • ENGINEERED OUTER DOMAIN (EOD) OF HIV GP120 AND MUTANTS THEREOF
    Publication number: 20190194262
    Abstract: The invention relates to an engineered outer domain (eOD) of HIV gp120 and mutants thereof and methods of making and using the same. The mutant eODs may be advantageous for the elicitation of CD4-binding site (CD4bs)-directed broadly-neutralizing antibodies (bnAbs) and/or improve binding to mature VRC01 and/or improve binding to germline VRC01 and the germlines of other VH1-2 derived broadly-neutralizing antibodies. The mutant eODs may also include glycan-masking mutations on eOD. The present invention also includes fusions of eOD to various protein multimers to enhance immunogenicity as well as the design of cocktails of different eODs that represent the full diversity of HIV sequences within the VRC01 epitope and surroundings.
    Type: Application
    Filed: March 4, 2019
    Publication date: June 27, 2019
    Inventors: Po-Ssu Huang, Joseph Graham Jardine, Sergey V. Menis, William Ray Schief, Neil P. King
  • Engineered outer domain (eOD) of HIV gp120 and mutants thereof
    Patent number: 10221217
    Abstract: The invention relates to an engineered outer domain (eOD) of HIV gp120 and mutants thereof and methods of making and using the same. The mutant eODs may be advantageous for the elicitation of CD4-binding site (CD4bs)-directed broadly-neutralizing antibodies (bnAbs) and/or improve binding to mature VRC01 and/or improve binding to germline VRC01 and the germlines of other VH1-2 derived broadly-neutralizing antibodies. The mutant eODs may also include glycan-masking mutations on eOD. The present invention also includes fusions of eOD to various protein multimers to enhance immunogenicity as well as the design of cocktails of different eODs that represent the full diversity of HIV sequences within the VRC01 epitope and surroundings.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: March 5, 2019
    Assignees: University of Washington, Center for Commercialization, The Scripps Research Institute, International AIDS Vaccine Initiative
    Inventors: Po-Ssu Huang, Joseph Graham Jardine, Sergey V. Menis, William Ray Schief, Neil P. King
  • ENGINEERED OUTER DOMAIN (EOD) OF HIV GP120 AND MUTANTS THEREOF
    Publication number: 20160185825
    Abstract: The invention relates to an engineered outer domain (eOD) of HIV gp120 and mutants thereof and methods of making and using the same. The mutant eODs may be advantageous for the elicitation of CD4-binding site (CD4bs)-directed broadly-neutralizing antibodies (bnAbs) and/or improve binding to mature VRC01 and/or improve binding to germline VRC01 and the germlines of other VH1-2 derived broadly-neutralizing antibodies. The mutant eODs may also include glycan-masking mutations on eOD. The present invention also includes fusions of eOD to various protein multimers to enhance immunogenicity as well as the design of cocktails of different eODs that represent the full diversity of HIV sequences within the VRC01 epitope and surroundings.
    Type: Application
    Filed: December 22, 2015
    Publication date: June 30, 2016
    Inventors: Po-Ssu Huang, Joseph Graham Jardine, Sergey V. Menis, William Ray Schief, Neil P. King
  • ENGINEERED OUTER DOMAIN (EOD) OF HIV GP120 AND MUTANTS THEREOF
    Publication number: 20140322269
    Abstract: The invention relates to an engineered outer domain (eOD) of HIV gp120 and mutants thereof and methods of making and using the same. The mutant eODs may be advantageous for the elicitation of CD4-binding site (CD4bs)-directed broadly-neutralizing antibodies (bnAbs) and/or improve binding to mature VRC01 and/or improve binding to germline VRC01 and the germlines of other VH1-2 derived broadly-neutralizing antibodies. The mutant eODs may also include glycan-masking mutations on eOD. The present invention also includes fusions of eOD to various protein multimers to enhance immunogenicity as well as the design of cocktails of different eODs that represent the full diversity of HIV sequences within the VRC01 epitope and surroundings.
    Type: Application
    Filed: April 11, 2014
    Publication date: October 30, 2014
    Applicants: University of Washington, International AIDS Vaccine Initiative, The Scripps Research Institute
    Inventors: Po-Ssu Huang, Joseph Graham Jardine, Sergey V. Menis, William Ray Schief, JR., Neil P. King